IE 11 is not supported. For an optimal experience visit our site on another browser.

Trius to Present at Future Leaders in the Biotech Industry

SAN DIEGO, April 13, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Friday, April 15th at 8:30 a.m. at the 18th Annual Future Leaders in Biotech Industry. The presentation will take place in New York at the Millennium Broadway Hotel.
/ Source: GlobeNewswire

SAN DIEGO, April 13, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Friday, April 15th at 8:30 a.m. at the 18th Annual Future Leaders in Biotech Industry. The presentation will take place in New York at the Millennium Broadway Hotel.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead investigational drug, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company's torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit .

CONTACT: Public Relations Contact: Jason Spark at Canale Communications, Inc. jason@canalecomm.com 619-849-6005 Investor Relations Contact: Stefan Loren at Westwicke Partners, LLC sloren@westwicke.com 443-213-0507